Pfizer - CDRD Innovation Fund (PCIF) Review Panel Committee
Pfizer Canada has provided CDRD with $3 million to launch the Pfizer-CDRD Innovation Fund (PCIF), which is aimed at accelerating the commercialization of promising academic research projects into high-value medicines that form the basis for new companies or licensing opportunities.
The role of the PCIF Review Panel Committee is to:
- assess the science, commercial benefit, and future economic value of projects,
- recommend to CDRD which projects should be funded, and
- review the progress of funded projects.
CDRD draws upon the broad range of expertise of the members of the Review Panel Committee, who represent industry, research institutions, Pfizer Canada, and CDRD.
PCIF Review Panel Committee Members
- Gregorio Aversa, Independent member - Principal, Abmedix Biomedical (Panel Chair)
- Marcel Bally, CDRD representative (Division Chair) - Head of Advanced Therapeutics, BC Cancer Agency
- Shaun Foy, Independent member - Former Partner, Nomura Phase4 Ventures
- Bettina Hamelin, Pfizer representative - Director, Regional R&D, Pfizer Canada Inc.
- Karim Lalji, Independent member - Senior Vice President, Commercial Affairs, Cardiome
- Michel Roberge, CDRD representative (Scientific Director) - Professor, UBC
- Terrance Snutch, Independent member - Professor and Canada Research Chair, Michael Smith Laboratories (UBC)
- Keith Walley, Independent member - Professor, iCAPTURE (UBC)
- Shane Weber, Pfizer representative - Director, Diagnostics, Molecular Medicine, Pfizer Inc.
- Robert Young, CDRD representative (Division Chair) - Professor, SFU, Merck Frosst-BC Discovery Chair in Pharmaceutical Genomics, Bioinformatics and Drug Discovery / Former Vice President of Medicinal Chemistry, Merck Frosst Canada